Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shipment Control Lifted for Pfizer's Methotrexate Injection After One Year
January 21, 2022
- Shionogi Submits PI Data for Oral COVID-19 Drug in Japan
January 21, 2022
- FunPep, EPS Group in Talks to Codevelop Peptide Drugs in China
January 21, 2022
- BMS’ Second CAR-T Therapy Abecma Approved in Japan
January 21, 2022
- Fuji Pharma Slapped with Biz Improvement Order over GMP Violations
January 20, 2022
- Daiichi Sankyo to Offload 8 US Assets to Cosette
January 20, 2022
- Katarzyna Maria Witkos Takes Helm at Alnylam Japan
January 20, 2022
- First Subject Enrolled in US PII/III of Anti-MTBR Tau Antibody for Alzheimer’s: Eisai
January 20, 2022
- AnGes/Vasomune's COVID-19 Med Enters PIIa for Severe Hospitalized Patients in US
January 20, 2022
- SymBio Seeks to Start PII Trial for Pediatric Adenovirus Infections in UK
January 19, 2022
- Mitsubishi Tanabe Earns Japan Rights for ADC Zynlonta
January 19, 2022
- Ono, Neurimmune Extend Drug Discovery Pact for Neurodegenerative Diseases
January 18, 2022
- Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
- Nipro Grabs Rights for Nexium Authorized Generic, Filing Done in August
January 18, 2022
- Enhertu Accepted for FDA Review for Second-Line Breast Cancer Use
January 18, 2022
- MSD, Kyorin to Copromote Oral COVID-19 Med Lagevrio in Japan from Jan. 31
January 18, 2022
- CSL Behring Files Prophylactic Treatment for HAE Attacks in Japan
January 17, 2022
- Pfizer Files Oral COVID-19 Pill in Japan
January 14, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for FDA Review in ALS
January 14, 2022
- Eisai “Strongly Opposes” Medicare Coverage Proposal for Aduhelm, Calls for Revisit
January 14, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…